BioSpace News Archive

The drugs target a protein called STING (stimulator of interferon genes), which plays an important role in the innate immune system, which is the body’s first line of defense against various pathogens.

The European Patent Office has granted a patent for Sangui’s proposed technology/treatment (SBT 102) for septic shock patients, effective March, 6, 2019*.

Reports Neurology Franchise Annual Net Sales of $110.3 million, at the High End of Guidance Range

In February, Galapagos NV Chief Executive Officer Onno van de Stolpe promised that 2019 will be a “data rich year” for the Belgium-based company and its lead product, filgotinib.

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Vanda Pharmaceuticals Inc. from November 4, 2015 through February 11, 2019, inclusive.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AVEO Pharmaceuticals, Inc. from August 4, 2016 through January 31, 2019, inclusive.

Forbius announced that the first patient has been dosed in a Phase 2a squamous cell carcinoma of the head and neck (SCCHN) clinical trial.

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Syneos Health, Inc. from May 10, 2017 through February 27, 2019, inclusive.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of persons or entities who sold WuXi PharmaTech Inc. securities between September 1, 2015 and December 10, 2015, both dates inclusive or purchased securities during the Class Period and held such shares through December 10, 2015.

This new application will be unveiled at the Vision Expo East (VEE) Conference in New York from March 21-24, 2019